Mercado mundial de tratamiento del cáncer colorrectal: tendencias de la industria y pronóstico hasta 2030

Análisis y tamaño del mercado de tratamiento del cáncer colorrectal

En el mundo actual, las enfermedades graves y potencialmente mortales son cada vez más frecuentes. El cáncer colorrectal es una de estas enfermedades graves, cuya prevalencia sigue aumentando a nivel mundial. Según la Organización Mundial de la Salud (OMS), se espera que para 2030 los casos de cáncer colorrectal aumenten en un 70 % a nivel mundial. El aumento de los trastornos por mutación genética y la adopción cada vez mayor de estilos de vida poco saludables que aumentan el riesgo de aparición de cáncer colorrectal también impulsan el crecimiento del mercado.

 Data Bridge Market Research analiza la tasa de crecimiento del mercado de tratamiento del cáncer colorrectal en el período de pronóstico 2023-2030. La CAGR esperada del mercado de tratamiento del cáncer colorrectal tiende a rondar el 4% en el período de pronóstico mencionado. El mercado está valorado en USD 19 mil millones en 2022 y crecería hasta USD 26 mil millones para 2030. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research también incluye un análisis de expertos en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de tratamiento del cáncer colorrectal

Market Definition

Colorectal cancer treatment involves a varied number of drugs that are responsible for the treatment of colorectal cancer. Colorectal cancer primarily affects the older adults however it can affect any age groups. Signs and symptoms related with the colorectal cancer are weight loss, weakness, abdominal discomfort, fatigue, pain, persistent change in the bowel habits including diarrhea and constipation, cramps, rectal bleeding, blood in the stools and others.

Colorectal Cancer Treatment Market Dynamics

Drivers

• Increasing Prevalence of Cancer

As per American Cancer Society, men tend to have a 1 in 23 lifetime risk of having colorectal cancer, whereas women have a 1 in 25. Women are at a moderately lower risk than men. Colorectal cancer is the third most frequent cancer in men and the second most common cancer in women. More than 1.8 million new cases were witnessed in 2018. People surviving with localized stage colorectal cancer tend to have a 90% chance of surviving after five years. About 39% of cases are diagnosed at this early stage. The 5-year survival rate is 71% if cancer ranges to neighbouring tissues, organs, or regional lymph nodes. Thus, this factor boost the market growth.

• Rising Healthcare Expenditure And Government Support

With the growing pervasiveness of cancer, the increasing awareness for the disease and the associated treatment is also rising. Government initiatives tend to provide better and more affordable treatments along with favourable reimbursement policies which are anticipated to boost the industry growth. Additionally, growing acceptance of advanced therapies such as Erbitux (cetuximab), Avastin (bevacizumab), and Stivarga (regorafenib) is estimated to drive the market. Amgen and Allergan’s Mvasi was the first biosimilar to Avastin which was approved in U.S. and Europe, therefore marking the entry of biosimilars in the sector of oncology. Numerous other bevacizumab and cetuximab biosimilars are under development and most likely to impact branded sales when launched.

Opportunities

• Developments in the Emerging Markets

Several market players primarily focus on developing markets such as Singapore and China as they have many colorectal cancer patients and increasing medical tourism. According to the Australian Institute of Health and Welfare, more than 15,540 new cases of colorectal cancer were diagnosed in 2021. Furthermore, according to the Malaysia Healthcare Travel Council, in 2019, more than 1.22 million healthcare travelers visited Malaysia for healthcare purposes. Furthermore, the decreasing cost of treatment and involvement of advanced technologies to provide less waiting time for several procedures are most likely to boost the number of surgeries. This as a result, increases the demand for the market.

• Increasing Options of Diagnostic Techniques

There are varied diagnostic techniques that boost the growth of the market. Fecal occult blood testing (FOBT) is the most extensively prescribed screening test for CRC since it is simple, non-invasive, and has been showed to decrease the chances of death because of CRC. For instance, Clinical Genomics Technologies Pty Ltd provides InSure ONE (Fecal Immunochemical testing) for identifying blood in the stool, which helps to diagnose CRC.

 Restraints/Challenges

• High Cost of Treatment

The growing expenditure associated with the medications impede the market growth. Several drugs and surgeries cost high, and people in the major emerging and underdeveloped countries cause the under treatment of numerous patients. This hampers the market growth.

This colorectal cancer treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the colorectal cancer treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2020, Taiho Pharmaceutical Co., Ltd. launched LONSURF which is an anticancer drug, to treat colorectal cancer patients in China. The company anticipated that Lonsurf would lead to patients and medical facilities as a pharmaceutical substitute for individuals having colorectal cancer.

Global Colorectal Cancer Treatment Market Scope

The colorectal cancer treatment market is segmented on the basis of treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Chemotherapy
• Targeted Therapy
• Radiation Therapy
• Surgery
• Immunotherapy
• Embolization
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Colorectal Cancer Treatment Market Regional Analysis/Insights

The colorectal cancer treatment market is analyzed and market size insights and trends are provided by treatment, route of administration, end-users and distribution channel as referenced above.

The major countries covered in the colorectal cancer treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for colorectal cancer treatment market throughout the forecasted period because of growing healthcare and R&D expenditure and market players on novel technology or formulation of existing drugs. As per the records of the American Cancer Society, 95,520 new colon cancer cases and 39,910 new rectal cancer cases were reported in the U.S. in 2017. Colorectal cancer is becoming more common in the U.S. because of the rising cases.

Asia-Pacific dominates the market because of the high incidence cases of cancer disorders and number of generic drugs. China and India are anticipated to play a major role in the Asia Pacific market. This is because of the huge population base and rising prevalence of colorectal cancer patients.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Colorectal Cancer Treatment Market Share Analysis

The colorectal cancer treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to colorectal cancer treatment market.

Los actores clave que operan en el mercado de tratamiento del cáncer colorrectal incluyen:

• Genentech, Inc. (Estados Unidos)
• Abbvie, Inc. (Estados Unidos)
• Novartis AG (Suiza)
• Industrias farmacéuticas Teva Ltd (Israel)
• Pfizer Inc (Estados Unidos)
• Hikma Pharmaceuticals PLC (Reino Unido)
• Alkem Labs Ltd (India)
• Accord Healthcare (Reino Unido)
• Grupo Zydus (India)
• Amneal Pharmaceutical Inc. (Reino Unido)
• Lilly (Estados Unidos)
• Sanofi (Francia)
• Bausch Health Companies Inc. (Canadá)
• Almirall, SA (España)
• Fresenius Kabi Estados Unidos (EE. UU.)
• Sagent Pharmaceuticals, Inc. (Estados Unidos)
• Hill Dermaceuticals, Inc. (Estados Unidos)
• Compañía Bristol-Myers Squibb (Estados Unidos)
• Amgen Inc. (Estados Unidos)

SKU-52891